Inflectra®/CT-P13* (infliximab) has increasing real-world evidence across induction, maintenance, switch and paediatric studies in IBD22,45-55.

Induction and Maintenance

Infliximab Real World Studies: Induction and Maintenance

Switch Studies

Infliximab Real World Studies: Switch Studies

Paediatric Studies

Infliximab Real World Studies: Paediatric Studies

All published studies, reports and study abstracts evaluating CT-P13 in IBD identified through April 2017#.

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
#Not all studies evaluated the efficacy and/or safety of CT-P13. The majority of studies were retrospective or prospective/ observational, and in most cases, CT-P13 results were compared against baseline parameters or prior evidence of Remicade®.

IBD, Inflammatory bowel disease.

 

PP-IFA-GBR-0306. December 2018